Patent · US Active

Method of using antibody polypeptides that antagonize CD40 to treat IBD

US10435475B2 · kind B2 · utility

9Cited by

13References

16Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Marek Honczarenko · Princeton, US
Vaishali Shah · Pennington, US
Xiaoni Liu · Yardley, US
Wendy L. Trigona · Princeton, US
Rong Shi · Princeton, US
Suzanne J. Suchard · Wilmington, US
Karen Price · Sauquoit, US
Linda M. Gustavson · Guilford, US

Key dates

Filing date	Mar 9, 2015
Grant date	Oct 8, 2019
Priority date	—
Expiry date	Feb 21, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.